Published within
|«
«
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
...
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
CommentWire
|
Wyeth's performance in 2002 was negatively affected by its heavy reliance on its Women's Health franchise. With the anticipated launch of Flumist, it is expected that 2003 will mark the beginning of Wyeth's transition from a reliance on HRT treatments to a more diversified portfolio.<BR />
Published By Datamonitor
|
05 Jun 2003 |
|
CommentWire
|
According to recent research, newly diagnosed patients with chronic myeloid leukaemia are nine times more likely to achieve a complete cytogenetic response when treated with Novartis' [NVS] Glivec than when treated with traditional combination therapy. The continued positive results mean that Glivec looks set to become a blockbuster.
Published By Datamonitor
|
10 Jun 2003 |
|
CommentWire
|
The continuing rollout of J&J's Evra marks an important development in the $4 billion hormonal contraception market. Oral pills have dominated the market for more than 40 years, but with competitive pricing, convenient dosing and the support of family planning organizations, the consumer friendly patch could shake everything up.
Published By Datamonitor
|
18 Jun 2003 |
|
CommentWire
|
The submission of Erbitux for marketing authorization in the European Union and Switzerland is the latest indication of a rally in ImClone Systems' [IMCL] fortunes following a rocky eighteen months. The European results also put ImClone's US licensing partner, Bristol Myers Squibb [BMY], a in a better position to try again for FDA approval.
Published By Datamonitor
|
16 Jul 2003 |
|
CommentWire
|
Roche's [ROCZ.S] bisphosphonate drug Bondronat has been recommended for the prevention of bone complications in patients with breast cancer and bone metastases by the EU advisory committee. Market authorization would significantly increase the drug's patient potential, but it is unlikely to threaten the supremacy of Novartis' [NVS] Zometa.
Published By Datamonitor
|
28 Jul 2003 |
|
CommentWire
|
Transgenic plant technologies could lead to a revolution in vaccine production and manufacture. Should plant-based vaccines prove effective in clinical trials, this will drive licensing activity between key vaccine players and companies with relevant intellectual property.
Published By Datamonitor
|
20 Aug 2003 |
|
CommentWire
|
Findings from three large-scale trials support the use of AstraZeneca's [AZN.L] new oral direct thrombin inhibitor, Exanta (ximelagatran), in post-MI and atrial fibrillation and the use of the angiotensin receptor blocker, Atacand (candesartan), in patients with heart failure. These results will further the company's stated aim to become the major cardiovascular player within the next five years.
Published By Datamonitor
|
04 Sep 2003 |
|
CommentWire
|
Bayer's [BAY.F] company structure has been modernized, with its conglomerate model streamlined to allow its four major components the freedom to operate independently and undergo M&A. However, the Healthcare division's portfolio is such that it may have trouble even finding a potential merger partner.
Published By Datamonitor
|
01 Oct 2003 |
|
CommentWire
|
UK Department of Health figures show that the rate of illness in the under-four age group is three times higher than among middle-aged and elderly people. Despite this, fewer than half of the one million children in at-risk categories have been immunized. If successful, fresh attempts to improve the production process may be able to improve the levels of immunization among children.
Published By Datamonitor
|
04 Dec 2003 |
|
CommentWire
|
AstraZeneca's [AZN.L] Iressa was billed as one of a new class of anti-tumor agents that would revolutionize the treatment of lung cancer. However, to date the drug has been disappointing and approvals continue to be for third-line treatment. If Iressa is to reach blockbuster status, it must reach patients as a first line therapy.
Published By Datamonitor
|
05 Jan 2004 |
|
|«
«
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
...
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.